Details for Patent: 10,398,693

Which drugs does patent 10,398,693 protect, and when does it expire?

Patent 10,398,693 protects ROZLYTREK and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 10,398,693

Title:	Pharmaceutical compositions and dosage forms
Abstract:	Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazi- n-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.
Inventor(s):	Codallos, Jr.; Daniel (San Diego, CA), Orr; Robert (San Clemente, CA), Li; Ching-Yuan (San Diego, CA), Start; Valerie Denise (San Diego, CA)
Assignee:	IGNYTA, INC. (San Diego, CA)
Application Number:	16/039,196
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,398,693

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-001	Aug 15, 2019		RX	Yes	No			Y
Genentech Inc	ROZLYTREK	entrectinib	CAPSULE;ORAL	212725-002	Aug 15, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 10,398,693

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018302170
Brazil	112020000793
Canada	3069339
China	110913842
European Patent Office	3654952
Israel	271759
Japan	2020527575